Description
Hexarelin was put together in the early 1990s by Romano Deghenghi and the Mediolanum Farmaceutici group in Milan, with later development passing through Pharmacia Italy. It carries the International Nonproprietary Name Examorelin, which is the label most pharmacological reference databases file the molecule under, even though almost nobody uses that name in the lab. The compound is a six-residue peptide with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, and that small methyl group on the tryptophan at position 2 is the entire reason it exists as a separate molecule rather than a footnote to GHRP-6.
The methyl group that makes the molecule
If you strip the 2-methyl out of the tryptophan, what is left is essentially GHRP-6. The 2-methyl-Trp modification slows enzymatic clearance and tightens the fit at the ghrelin receptor (GHS-R1a), and in published rat pituitary work Examorelin came out roughly an order of magnitude more potent per microgram than the parent compound on acute GH release. That difference is the headline data point in nearly every comparison paper in the Deghenghi files.
The CD36 side door
Most ghrelin-family work treats GHS-R1a as the only address the molecule visits. Hexarelin is unusual because it also binds CD36, the fatty acid translocase expressed on cardiomyocytes and macrophages, and a chunk of the published research on this peptide is built around that off-target site. The cardioprotection signal in rat infarct and isolated heart models, including work by Berti and the Locatelli group in Milan, traces back to CD36 binding rather than to the pituitary axis. If you are pulling references for a cardiac protocol rather than a somatotroph one, that is where the relevant literature sits.
Acute response, chronic attenuation
One of the consistent observations in the older human and animal pharmacology files is that the GH response to repeated Hexarelin dosing flattens over weeks of continuous exposure, while the acute single-dose response stays sharp. That is a useful design point for any study that runs longer than a few days, and it is the reason the molecule found its diagnostic niche in GH provocation testing rather than as a long-run secretagogue tool.
Reference points for the order
- CAS 140703-51-1, free base molecular weight 887.04 g/mol
- Sequence His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 as the acetate salt
- GHS-R1a agonist, with documented CD36 binding as a secondary site
- Acute potency higher than GHRP-6; chronic GH response known to attenuate
The vial itself
Each unit is lyophilised Examorelin acetate. Synthesis comes through UK and EU peptide manufacturers we have held long-running supply relationships with, never relabelled bulk from open marketplaces. Every batch is released against HPLC for purity and mass spectrometry for identity, and the CoA carrying the lot number printed on your vial can be requested through live chat before or after the order. If a vial ever fails to match its CoA on independent testing, the order is refunded in full.
Getting it to the bench
Around nine in ten UK orders leave the warehouse and reach the customer inside 48 hours. Live chat is run by people in UK working hours who can pull batch paperwork while you are still on the line. For studies needing ten vials or more, contact support directly rather than stacking the cart at retail, and pricing is reworked from there.
Sold strictly for in vitro laboratory research. Not for human or veterinary use. UK 18+.
